|
|
|
CAPN - Capnia, Inc.
Capnia,
Inc. is a biotechnology company that develops and commercializes
innovative diagnostic and therapeutic products for respiratory and
critical care markets. The company's technology platform is based on
its proprietary carbon dioxide (CO2) management technology, which
enables the use of CO2 as a medical tool for diagnostic and
therapeutic purposes.
Capnia's lead product candidate is the
CoSense system, a non-invasive device that measures the exhaled CO2
levels in a patient's breath to monitor the effectiveness of treatment
for carbon monoxide poisoning. The CoSense system has been approved by
the FDA and is currently being marketed in the United States.
The company is also developing the Serenz system, a handheld device
that delivers a non-invasive, low-dose CO2 stream to the nasal
passages to treat the symptoms of allergic rhinitis, a common
condition that causes inflammation of the nasal passages. The Serenz
system is currently in clinical trials and has not yet been approved
by the FDA.
Capnia was founded in 2005 and is headquartered in
Redwood City, California. The company is publicly traded on the NASDAQ
exchange under the ticker symbol "
|
|
|
|
|
